Researchers at the American College of Cardiology's annual meeting used proteomic approaches to uncover dysregulated signaling pathways in the disease.
The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...
CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.
Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...
The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...
With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-toleratedThe approval was ...
BridgeBio Pharma (BBIO) announced the Japanese Ministry of Health, Labour and Welfare, MHLW, has approved acoramidis, under the brand name ...
Amvuttra operates via RNA interference (RNAi), a groundbreaking technology that inhibits the production of the TTR protein in ...
The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of ...
The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...
CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback